ECSP099326A - Compuestos de pirazol y triazol sustituidos como inhibidores de ksp - Google Patents

Compuestos de pirazol y triazol sustituidos como inhibidores de ksp

Info

Publication number
ECSP099326A
ECSP099326A EC2009009326A ECSP099326A ECSP099326A EC SP099326 A ECSP099326 A EC SP099326A EC 2009009326 A EC2009009326 A EC 2009009326A EC SP099326 A ECSP099326 A EC SP099326A EC SP099326 A ECSP099326 A EC SP099326A
Authority
EC
Ecuador
Prior art keywords
pirazol
ksp inhibitors
compounds replaced
triazol compounds
triazol
Prior art date
Application number
EC2009009326A
Other languages
English (en)
Inventor
Paul A Barsanti
Kris Mendenhall
Paul Renhowe
David Duhl
Annette Walter
Yi Xia
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP099326A publication Critical patent/ECSP099326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer nuevos compuestos de pirazol y triazol sustituidos de la fórmula (I), y sales farmacéuticamente aceptables, ésteres o pro-fármacos de los mismos, composiciones de los derivados junto con vehículos farmacéuticamente aceptables, y usos de los mismos.
EC2009009326A 2006-11-13 2009-05-13 Compuestos de pirazol y triazol sustituidos como inhibidores de ksp ECSP099326A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
ECSP099326A true ECSP099326A (es) 2009-06-30

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009326A ECSP099326A (es) 2006-11-13 2009-05-13 Compuestos de pirazol y triazol sustituidos como inhibidores de ksp

Country Status (32)

Country Link
US (2) US8129358B2 (es)
EP (1) EP2091926B1 (es)
JP (1) JP5264755B2 (es)
KR (1) KR20090081020A (es)
CN (1) CN101558049B (es)
AR (1) AR063805A1 (es)
AU (1) AU2007323998B2 (es)
BR (1) BRPI0719002A2 (es)
CA (1) CA2668661A1 (es)
CL (1) CL2007003272A1 (es)
CO (1) CO6382171A2 (es)
CR (1) CR10787A (es)
DO (1) DOP2009000106A (es)
EA (1) EA017748B1 (es)
EC (1) ECSP099326A (es)
ES (1) ES2557478T3 (es)
GE (1) GEP20125389B (es)
GT (1) GT200900122A (es)
HN (1) HN2009000968A (es)
IL (1) IL198471A0 (es)
MA (1) MA30959B1 (es)
MX (1) MX2009005071A (es)
NI (1) NI200900084A (es)
NO (1) NO20092226L (es)
NZ (1) NZ576640A (es)
PE (1) PE20081169A1 (es)
SM (1) SMP200900045B (es)
TN (1) TN2009000178A1 (es)
TW (1) TW200831480A (es)
UA (1) UA97256C2 (es)
WO (1) WO2008063912A1 (es)
ZA (1) ZA200902940B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20125389B (en) * 2006-11-13 2012-01-25 Novartis Ag Substituted pyrazole and triazole compounds as ksp inhibitors
WO2008086122A2 (en) * 2007-01-05 2008-07-17 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物
CN103153970A (zh) * 2010-04-15 2013-06-12 诺瓦提斯公司 作为ksp抑制剂的*唑和噻唑化合物
BR112015012843B8 (pt) * 2012-12-05 2023-04-25 Merck Sharp & Dohme Método para sintetizar o composto
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
CA2930585A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
EP3386973B1 (en) * 2015-12-11 2020-08-12 Syngenta Participations AG Pesticidally active 1,2,4-triazole derivatives
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) * 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
WO2000059887A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
BR0015110A (pt) 1999-10-27 2002-07-02 Cytokinetics Inc Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001296799A1 (en) 2000-10-06 2002-04-15 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
EP1351671A1 (en) 2001-01-19 2003-10-15 Cytokinetics, Inc. Triphenylmethane kinesin inhibitors
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
WO2003039480A2 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
ES2291543T3 (es) 2001-12-06 2008-03-01 MERCK & CO., INC. Inhibicion de kinesina mitotica.
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
DE60231439D1 (de) 2001-12-06 2009-04-16 Merck & Co Inc Mitotische kinesinhemmer
DE60234278D1 (de) 2001-12-06 2009-12-17 Merck & Co Inc Mitotische kinesin-hemmer
CA2467726A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002357114B2 (en) * 2001-12-07 2008-07-24 Virginia Commonwealth University Treatment of neoplasia
CA2472470A1 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
CA2475879A1 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
ATE448207T1 (de) 2002-03-08 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
PL373412A1 (en) 2002-05-09 2005-08-22 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods of their use for treating cellular proliferative diseases
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
US7038048B2 (en) 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
PL374190A1 (en) 2002-06-14 2005-10-03 Merck & Co, Inc. Mitotic kinesin inhibitors
CA2486215A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
WO2004004652A2 (en) 2002-07-08 2004-01-15 Merck & Co., Inc. Mitotic kinesin binding site
DE60326248D1 (de) 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2005536553A (ja) 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004024086A2 (en) 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
US20080021079A1 (en) 2003-05-07 2008-01-24 Han-Jie Zhou Compounds, Compositions, and Methods
JP2007500746A (ja) 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
PT1732926E (pt) * 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
AU2005245492A1 (en) * 2004-05-21 2005-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
RU2427572C2 (ru) * 2004-06-18 2011-08-27 Чирон Корпорейшн N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака
EP2275412A1 (en) * 2004-10-19 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
TW200800951A (en) * 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
GEP20125389B (en) * 2006-11-13 2012-01-25 Novartis Ag Substituted pyrazole and triazole compounds as ksp inhibitors

Also Published As

Publication number Publication date
AR063805A1 (es) 2009-02-18
UA97256C2 (ru) 2012-01-25
TN2009000178A1 (en) 2010-10-18
SMP200900045B (it) 2010-03-01
EA200900631A1 (ru) 2009-12-30
NI200900084A (es) 2010-01-29
ES2557478T3 (es) 2016-01-26
CL2007003272A1 (es) 2008-03-24
IL198471A0 (en) 2010-02-17
EP2091926B1 (en) 2015-10-21
MA30959B1 (fr) 2009-12-01
KR20090081020A (ko) 2009-07-27
HN2009000968A (es) 2011-10-25
SMAP200900045A (it) 2009-07-14
PE20081169A1 (es) 2008-09-24
NZ576640A (en) 2011-10-28
TW200831480A (en) 2008-08-01
ZA200902940B (en) 2010-05-26
JP5264755B2 (ja) 2013-08-14
WO2008063912A1 (en) 2008-05-29
US8129358B2 (en) 2012-03-06
CO6382171A2 (es) 2012-02-15
AU2007323998A1 (en) 2008-05-29
US7902240B2 (en) 2011-03-08
CR10787A (es) 2009-07-02
GEP20125389B (en) 2012-01-25
US20100034813A1 (en) 2010-02-11
CN101558049A (zh) 2009-10-14
US20080200462A1 (en) 2008-08-21
CA2668661A1 (en) 2008-05-29
GT200900122A (es) 2011-09-14
MX2009005071A (es) 2009-05-25
CN101558049B (zh) 2012-08-15
EP2091926A1 (en) 2009-08-26
BRPI0719002A2 (pt) 2013-12-17
JP2010509365A (ja) 2010-03-25
AU2007323998B2 (en) 2011-09-22
DOP2009000106A (es) 2009-05-31
EA017748B1 (ru) 2013-02-28
NO20092226L (no) 2009-08-12

Similar Documents

Publication Publication Date Title
ECSP099326A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp
DOP2009000169A (es) Derivados ciclados como inhibidores de eg-5
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
CR20140215A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
ECSP088549A (es) Nuevos derivados de pirrol fusionado
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
UY31189A1 (es) Compuestos heterocíclicos
TW200612958A (en) Substituted imidazole derivatives
ECSP055729A (es) Nuevos inhibidores biciclicos de la lipasa sensible a hormonas
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
CR20120130A (es) Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso
SV2011003916A (es) Nuevas lactamas como inhibidores de beta secretasa
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
AR061740A1 (es) Nuevos derivados naftalenicos, su procedimiento de praparacion y las composiciones farmaceuticas que los contienen
GT200800296A (es) Derivados de ácido fenilacético
CU20100125A7 (es) Derivados bis-(sulfonilamino) para uso en terapia